NightHawk Biosciences, Inc. (NHWK)
Chart Events
Performance Outlook
| Previous Close | 2.3600 |
| Open | 2.3400 |
| Bid | 2.3300 x 1100 |
| Ask | 2.3400 x 1200 |
| Day's Range | 2.2154 - 2.3492 |
| 52 Week Range | 1.6000 - 10.8500 |
| Volume | |
| Avg. Volume | 146,838 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks Small Cap Research
NHWK: Name Change and New Facility
By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT The recently renamed NightHawk Biosciences, Inc. (NYSE:NHWK) reported first quarter 2022 results on May 16, 2022 and filed its Form 10-Q with the SEC. It has been a whirlwind year for the company as it made an acquisition, expanded its manufacturing efforts, converted into a vertically integrated biosciences company and
- GlobeNewswire
NightHawk Biosciences Provides First Quarter 2022 Business Update
DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the first quarter ended March 31, 2022. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We are extremely proud of the progress we have made this quarter to transition NightHawk into a fully-integrated biopha
- GlobeNewswire
NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk’s Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston. PTX-35 i
